A combination that includes: a flavonoid, for example in an amount from about 0.1 g to about 1.5 g; and one or more of: ascorbic acid, ascorbate, or a combination thereof, for example in an amount from about 0.2 g to about 2.0 g; N-acetyl cysteine, for example in an amount from about 0.10 g to about 1.2 g; alpha-lipoic acid, for example in an amount from about 0.05 g to about 0.60 g; and at least one carotenoid, for example in an amount from about 1 mg to about 50 mg. The combination may be used to mitigate or prevent nuclear DNA damage, mitochondrial DNA damage, lipid peroxidation, protein carbonylation, or any combination thereof in a subject caused by oxidative stress.

The present disclosure relates to compositions of phytonutrients and methods of treating obesity by administering these compositions to subjects in need thereof. The compositions described herein are rationally designed compositions of phytonutrients that interfere with fat cell differentiation, a process commonly known as “adipogenesis”, to prevent weight gain and improve glycemic control. The phytonutrients are rationally combined based on their complementary effects on the expression level of six adipogenic biomarker proteins. Exemplary compositions can include one or more of berberine, luteolin, resveratrol, fisetin, quercetin, fucoidan, epigallocatechin gallate (EGCG), hesperidin, or curcumin.

The present disclosure relates to compositions of phytonutrients and methods of treating obesity by administering these compositions to subjects in need thereof. The compositions described herein are rationally designed compositions of phytonutrients that interfere with fat cell differentiation, a process commonly known as “adipogenesis”, to prevent weight gain and improve glycemic control. The phytonutrients are rationally combined based on their complementary effects on the expression level of six adipogenic biomarker proteins. Exemplary compositions can include one or more of berberine, luteolin, resveratrol, fisetin, quercetin, fucoidan, epigallocatechin gallate (EGCG), hesperidin, or curcumin.

The subject matter described herein is directed to stable L-cysteine compositions for injection, comprising: L-cysteine or a pharmaceutically acceptable salt thereof and/or hydrate thereof in an amount from about 10 mg/mL to about 100 mg/mL; Aluminum in an amount from about 1.0 parts per billion (ppb) to about 250 ppb; cysteine in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; pyruvic acid in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; a pharmaceutically acceptable carrier, comprising water; headspace O.sub.2 that is less than 1.0%; dissolved oxygen present in the carrier in an amount from about 0.01 parts per million (ppm) to about 1 ppm, wherein the composition is enclosed in a single-use container having a volume of from 10 mL to 100 mL. Also described are compositions for a total parenteral nutrition regimen and methods for their use.

The invention relates to carrier complexes and methods for delivering molecules to cells. The carrier complexes comprises a molecule and an aromatic cationic peptide in accordance with the invention. In one embodiment, the method for delivering a molecule to a cell comprises contacting the cell with a carrier complex. In another embodiment, the method for delivering a molecule to a cell comprises contacting the cell with a molecule and an aromatic cationic peptide.

The invention provides ingestible particles comprising a water-swellable or water-soluble polymeric component, a lipid component, and optionally an amino acid, a vitamin and/or a micro-nutrient. The polymeric component may be embedded in the lipid component. The particle may further comprise an inert core and/or an outer layer which rapidly disintegrates after oral ingestion. The invention further provides methods for preparing the ingestible particles and uses thereof.

A iontophoresis method (700) is described for delivering vitamin C through the skin of a biological subject, the method comprising applying (702) a selected current profile, either continuous direct current or pulsed current or a combination of both to a biological subject. A iontophoresis composition is further described, comprising one or more of vitamin C, vitamin C derivatives, ions of vitamin C and ions of vitamin C derivatives and further comprising a silicon material and water. A iontophoresis kit for carrying out the iontophoresis method is also disclosed. The application further describes a iontophoresis device comprising an electrode assembly and circuitry configured to concurrently generate a continuous direct current stimulus and a pulsed current stimulus; a corresponding iontophoresis method for delivering a cosmetic composition to a biological subject is also disclosed.

Methods and compositions for treating bariatric surgery patients, and for treating or preventing complications associated with such patients, are disclosed.

Methods and compositions for treating bariatric surgery patients, and for treating or preventing complications associated with such patients, are disclosed.

The present invention aims to provide a therapeutic agent for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and fibromyalgia.

A therapeutic agent for a disease selected from myalgic encephalomyelitis/chronic fatigue syndrome, and fibromyalgia. containing 2-amino-2-[2-(4-heptyloxy-3-trifluoromethylphenyl)ethyl]propane-1,3-diol or a pharmaceutically acceptable salt thereof.